Sumitomo Mitsui Trust Group Inc. Sells 57,339 Shares of Personalis, Inc. (NASDAQ:PSNL)

Sumitomo Mitsui Trust Group Inc. trimmed its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 7.8% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 675,974 shares of the company's stock after selling 57,339 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.77% of Personalis worth $2,373,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Jefferies Financial Group Inc. grew its position in shares of Personalis by 104.1% during the 4th quarter. Jefferies Financial Group Inc. now owns 39,600 shares of the company's stock valued at $229,000 after acquiring an additional 20,200 shares during the period. Alpine Global Management LLC bought a new position in shares of Personalis during the 4th quarter valued at approximately $60,000. Williams Jones Wealth Management LLC. lifted its stake in shares of Personalis by 765.0% during the 4th quarter. Williams Jones Wealth Management LLC. now owns 134,072 shares of the company's stock valued at $775,000 after buying an additional 118,572 shares in the last quarter. Squarepoint Ops LLC lifted its stake in shares of Personalis by 438.7% during the 4th quarter. Squarepoint Ops LLC now owns 91,684 shares of the company's stock valued at $530,000 after buying an additional 74,664 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in shares of Personalis by 25.6% during the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company's stock valued at $198,000 after buying an additional 7,000 shares in the last quarter. 61.91% of the stock is owned by institutional investors.

Personalis Stock Performance

NASDAQ PSNL traded down $0.77 on Monday, hitting $6.68. The stock had a trading volume of 1,944,382 shares, compared to its average volume of 1,146,530. Personalis, Inc. has a 52-week low of $1.41 and a 52-week high of $7.79. The company has a market capitalization of $589.98 million, a price-to-earnings ratio of -5.18 and a beta of 1.95. The firm has a 50-day moving average of $5.42 and a 200-day moving average of $4.85.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. Personalis had a negative net margin of 98.10% and a negative return on equity of 48.78%. The business had revenue of $20.61 million for the quarter, compared to analysts' expectations of $17.41 million. As a group, research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on PSNL shares. Needham & Company LLC restated a "buy" rating and set a $7.00 price target on shares of Personalis in a research note on Thursday, April 10th. HC Wainwright upped their price target on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, May 7th. Guggenheim started coverage on shares of Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 price target on the stock. Finally, Craig Hallum started coverage on shares of Personalis in a research note on Monday, March 17th. They set a "buy" rating and a $8.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $7.67.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.